These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 355881)

  • 21. Comparing methods for calculating confidence intervals for vaccine efficacy.
    Ewell M
    Stat Med; 1996 Nov 15-30; 15(21-22):2379-92. PubMed ID: 8931208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimising the design of phase II oncology trials: the importance of randomisation.
    Ratain MJ; Sargent DJ
    Eur J Cancer; 2009 Jan; 45(2):275-80. PubMed ID: 19059773
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A survey of clinical trials of antibiotic prophylaxis in colon surgery: evidence against further use of no-treatment controls.
    Baum ML; Anish DS; Chalmers TC; Sacks HS; Smith H; Fagerstrom RM
    N Engl J Med; 1981 Oct; 305(14):795-9. PubMed ID: 7266633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal and minimax three-stage designs for phase II oncology clinical trials.
    Chen K; Shan M
    Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Active-controlled, non-inferiority trials in oncology: arbitrary limits, infeasible sample sizes and uninformative data analysis. is there another way?
    Carroll KJ
    Pharm Stat; 2006; 5(4):283-93. PubMed ID: 17128427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvement in the quality of randomized controlled trials among general anesthesiology journals 2000 to 2006: a 6-year follow-up.
    Greenfield ML; Mhyre JM; Mashour GA; Blum JM; Yen EC; Rosenberg AL
    Anesth Analg; 2009 Jun; 108(6):1916-21. PubMed ID: 19448222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implications of genetic traits on vaccine efficacy.
    Murthy BN
    Stat Med; 2003 Jun; 22(12):1989-98. PubMed ID: 12802817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical research in general medical journals: a 30-year perspective.
    Fletcher RH; Fletcher SW
    N Engl J Med; 1979 Jul; 301(4):180-3. PubMed ID: 377076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sensitivity and specificity of clinical trials. Randomized v historical controls.
    Sacks HS; Chalmers TC; Smith H
    Arch Intern Med; 1983 Apr; 143(4):753-5. PubMed ID: 6838297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design of adaptive two-stage double-arm clinical trials for dichotomous variables.
    Jiang Z; Xue F; Li C; Wang L; Cai H; Zhang C; Xia J
    Contemp Clin Trials; 2010 May; 31(3):242-50. PubMed ID: 20172053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bias in treatment assignment in controlled clinical trials.
    Chalmers TC; Celano P; Sacks HS; Smith H
    N Engl J Med; 1983 Dec; 309(22):1358-61. PubMed ID: 6633598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Power and sample size when multiple endpoints are considered.
    Senn S; Bretz F
    Pharm Stat; 2007; 6(3):161-70. PubMed ID: 17674404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inverse probability-of-censoring weights for the correction of time-varying noncompliance in the effect of randomized highly active antiretroviral therapy on incident AIDS or death.
    Cain LE; Cole SR
    Stat Med; 2009 May; 28(12):1725-38. PubMed ID: 19347843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sample size determination for assessing equivalence based on proportion ratio under a randomized trial with non-compliance and missing outcomes.
    Lui KJ; Chang KC
    Stat Med; 2008 Jan; 27(1):47-67. PubMed ID: 17708514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methods for one-sided testing of the difference between proportions and sample size considerations related to non-inferiority clinical trials.
    Dann RS; Koch GG
    Pharm Stat; 2008; 7(2):130-41. PubMed ID: 17526060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A three-stage clinical trial design for rare disorders.
    Honkanen VE; Siegel AF; Szalai JP; Berger V; Feldman BM; Siegel JN
    Stat Med; 2001 Oct; 20(20):3009-21. PubMed ID: 11590629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inadequate size of 'negative' clinical trials in dermatology.
    Williams HC; Seed P
    Br J Dermatol; 1993 Mar; 128(3):317-26. PubMed ID: 8471517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal two-stage designs for clinical trials with binary response.
    Thall PF; Simon R; Ellenberg SS; Shrager R
    Stat Med; 1988 May; 7(5):571-9. PubMed ID: 3387716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypothesis testing in neurosurgical trials.
    Sundaresan N; Voorhies R; Kwok KL; Thaler HT
    J Neurosurg; 1981 Apr; 54(4):468-72. PubMed ID: 7205348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.